HOUSTON, Oct. 22, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced the appointment of Niquette
Hunt to its Board of Directors. Ms. Hunt currently
serves as President and CEO of Candesant Biomedical.
"We are thrilled to add Ms. Hunt to our Board of Directors,"
commented Dr. Christopher Capelli,
Soliton Co-Founder and CEO. "We believe her extensive experience in
the medical device and aesthetics industries, which includes
successfully launching over twenty products and building sound
relationships with physicians in our marketplace, will prove
invaluable to our ongoing commercialization efforts."
Ms. Hunt brings more than 25 years of general management and
commercialization experience leading consumer product and
biotechnology companies. Coming out of line management in
both large corporations and start-ups, Ms. Hunt has proven her
ability to drive significant growth on a variety of businesses
across multiple industries.
Ms. Hunt founded Candesant Biomedical in 2016 to develop a
novel, non-invasive treatment for those who suffer from excessive
sweating. She has guided the company through product
development, Series A financing and is now focused on pre
commercialization efforts targeting the $2B market opportunity. Prior to Candesant,
Ms. Hunt was on the executive management team that took Revance
Therapeutics public raising over $250M in the IPO and follow-on financings.
Ms. Hunt started her career at Procter & Gamble and
Warner Lambert where she managed
market leading brands such as Head and Shoulders and Lubriderm.
"I could not be more pleased to join the Soliton Board," said
Ms. Hunt, "I am thrilled to be joining a team with such novel
technology that appears to have the potential to disrupt the
aesthetic space with a non-invasive, effective treatment for both
tattoo removal and cellulite reduction, if approved. I am excited
to apply the learnings from my collective experiences to help
Soliton successfully launch their products."
Join our more than 200K
subscribers here to follow the Company:
https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer
Center. The Company's first FDA cleared commercial product will use
rapid pulses of acoustic shockwaves as an accessory to lasers for
the removal of unwanted tattoos. The Company is based in
Houston, Texas, and is actively
engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the
market. The Company believes this "Soliton" method has the
potential to lower tattoo removal costs for patients, while
increasing profitability to practitioners, compared to current
laser removal methods. Soliton has completed a clinical study
using the RAP device to improve the appearance of cellulite and is
investigating potential additional capabilities of the RAP
technology. The device is currently cleared in the United States only for use in tattoo
removal and is not yet cleared for use to address cellulite.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. These statements relate to future events,
future expectations, plans and prospects. Although Soliton believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, actual results or outcomes may
prove to be materially different from the expectations expressed or
implied by such forward-looking statements. Soliton has attempted
to identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' "would," ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
in our filings with the Securities and Exchange Commission ("SEC"),
including under the heading " Risk Factors" in the Form 10-K for
year ended December 31, 2019 filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-appoints-niquette-hunt-to-board-of-directors-301157214.html
SOURCE Soliton, Inc.